Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 14, 2007. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares in accordance with shareholder authority granted at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 675,000 ordinary shares of 25 pence each.
- Purchase Date: February 14, 2007.
- Purchase Price: 1,481.8479 pence per share.
- Treasury Holdings Post-Purchase: 251,647,678 shares.
- Shares in Issue (Excluding Treasury): 5,751,959,336 shares.
Material Changes
The material change reported is the reduction of outstanding shares through the acquisition of 675,000 shares for the Treasury. The filing does not provide comparative data against prior periods for financial performance or other operational metrics.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Transparency Directive's transitional provision 6.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (251,647,678) against subsequent filings to track ongoing buyback activity.
- Confirm the total voting rights denominator (5,751,959,336 shares) for compliance with Financial Services Authority Disclosure and Transparency Rules.
- Note that this filing is a transactional report and does not contain quarterly or annual financial performance data.